Although asparaginase, a drug that depletes serum asparagine, has been successfully applied in the clinical treatment of acute lymphoblastic leukemia (ALL), its efficacy in solid tumors such as gastric cancer is limited. This evidence concerns the gene ASPG and gastric cancer.